OptimizeRx to Present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021
The company’s presentation will be available on-demand via the H.C. Wainwright conference portal here and in the investor relations section at investors.optimizerx.com beginning at
Management will discuss the company’s expanding addressable market due to the launch of new digital health solutions, and how an increasing number of enterprise-level, recurring revenue engagements are keeping the company on track for another year of record growth.
Register for the conference here. To schedule a one-on-one meeting, please contact your
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Tel (248) 651-6568 (x807)
Media Relations Contact
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070
Investor Relations Contact
Tel (949) 432-7557
Source: OptimizeRx Corporation